

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner : Samuel C. Woolwine  
Art Unit : 1637  
Applicants : Alastair Dixon  
Michael Skynner  
Serial No. : 10/520,693  
Filed : January 7, 2005  
For : Nucleic Acid Amplification Method

Commissioner for Patents  
P.O. Box 1450  
Alexandria  
VA 22313-1450

**DECLARATION OF PETER RICHARDSON UNDER 37 CFR §1.132**

Sir:

I, Peter J. Richardson, of Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QJ, United Kingdom, hereby declare that:

THAT, I have read and understood the specification and pending claims of the subject application;


AND, being thus duly qualified, do further declare:

1. I am the co-inventor of Richardson *et al.* (WO 01/06004).
2. The method disclosed in claim 1 of the subject application has unexpected and unobvious advantages when compared to the procedure described in Richardson *et al.*. These are detailed below.

3. The method disclosed in the subject application is easier to perform and more efficient than that described in Richardson *et al.*; the reverse transcription proceeds more efficiently, and fewer amplification cycles are required.
4. Unlike the procedure described in Richardson *et al.*, the need for rare restriction sites is avoided in the procedure described in the subject application.
5. In the procedure described in the subject application, the production of complex products is minimized, due in part to the use of unique sequences in FAP and TAP which are absent from the genome being investigated. Moreover, while the procedure of Richardson *et al.* uses a single primer to amplify the products after reverse transcription and second strand synthesis, the method of the subject application provides the significant advantage that two separate primers of unique sequence are used.
6. The procedure of the subject application not only provides greater amplification but also greater flexibility in use. For example, it readily allows the inclusion of specific restriction sites, for lambda cloning, for the manufacture of single cell libraries. Again, specific restriction sites can be included, for fragmentation, for use as probes on the microarrays and filters. The procedure can readily be linked to a protocol for laser capture microdissection.
7. At the filing date of the subject application, I would not have expected that combining the reverse transcription and amplification steps of the method of Richardson *et al.*, would have resulted in the advantages described in points 3-6.

The undersigned declares further that all statements made herein of his own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardise the validity of the Application or any Patent issuing thereon.

Further declarant sayeth naught

Signed:  Date: Aug 4<sup>th</sup> 2008

By: Peter J. Richardson